Biotech Values

[DewDiligence]

Re: Mircera

>We also know that amgen is running into safety problems etc. with these products. What would happen if we found out that cera did not have these common problems just like the similar to the vioxx and celebrex story. The patents in question are more in the manufacturing phase than the patient stage. Could Amgen be forced to allow cera come to market and be paid a percentage?<

I don’t think so. The relative merit of the two drugs from a medical standpoint would seem to be a separate issue from the patent litigation.